Although this group of mRNA-suppressed cases may not completely overlap with colorectal cancers that show CDX2 loss at the protein level by IHC, a close approximation should allow for the use of IHC for defining the group in clinical practice and, subsequently, assaying for alterations with clinical targetability as specific inhibitors are introduced in the clinic. Here, CDX2 is linked to colorectal cancer.